Barry Richard 4

What Happened

• Barry Richard, a director of Sarepta Therapeutics, was granted 16,875 restricted stock units (RSUs) on June 4, 2026. The Form 4 records this as an award (transaction code A). No purchase price or aggregate dollar value is listed—RSUs are not an open-market buy or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-05 (appears timely).
• Type: Award/Grant (RSUs) — 16,875 units; Price/value: N/A (not disclosed).
• Shares owned after transaction: not reported in the filing.
• Footnote: Each RSU represents the right to one share. Vesting occurs on the earlier of the one‑year anniversary of the grant or the next annual meeting of stockholders that is at least 50 weeks after the prior meeting.
• No 10b5-1 plan, tax-withholding, or late-filing flags are indicated in the filing.

Context

• RSUs convert into actual shares only when they vest and are typically used as compensation for directors and employees; they do not represent an immediate market purchase or sale. Such grants are routine corporate compensation and should be viewed as awarded equity rather than a direct signal of insider buying or selling.